Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06481306 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
A Phase 1 study of Healthy Volunteers and Anemia, Sickle Cell, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 184
- Enrollment target
- 19
- Study locations
NCT06481306: Recruiting Phase 1 study of Healthy Volunteers and Anemia, Sickle Cell, sponsored by Bristol-Myers Squibb.
NCT06481306 is a Phase 1 study of Healthy Volunteers and Anemia, Sickle Cell that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 184 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (62% lower). The trial reports 19 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06481306, a Phase 1 study of Healthy Volunteers and Anemia, Sickle Cell, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 184 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BMS-986470
- DRUG Famotidine
Study Locations (19)
Other
- Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone - Marseille
- Hôpital Universitaire Necker Enfants Malades - Paris
- Local Institution - 0005 - Leeds
California
- University of California San Diego - La Jolla - La Jolla
- UCSF Benioff Children's Hospital Oakland - Oakland
Massachusetts
- Local Institution - 0024 - Boston
- Boston Medical Center - Boston
Pennsylvania
- Thomas Jefferson University - Medicine/GI and Hepatology - Philadelphia
- Local Institution - 0032 - Pittsburgh
Virginia
- Inova Schar Cancer Institute - Fairfax
- Virginia Commonwealth University (VCU) Medical Center - Richmond
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Yale-New Haven Hospital - New Haven
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2024-07-17 |
| Est. Completion | 2027-11-16 |
| Phase | Phase 1 |
What NCT06481306 shows while recruiting
NCT06481306 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06481306 lists 19 locations in 13 states (Other, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06481306 about?
NCT06481306 is a clinical study titled "A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease". The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
What is the current status of trial NCT06481306?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 184 participants. The study started on 2024-07-17. Estimated completion is 2027-11-16.
What conditions does trial NCT06481306 study?
This clinical trial studies the following conditions: Healthy Volunteers, Anemia, Sickle Cell.
What interventions are being tested in trial NCT06481306?
The interventions under investigation include: Placebo (DRUG), BMS-986470 (DRUG), Famotidine (DRUG).
Who is sponsoring clinical trial NCT06481306?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06481306 being conducted?
This trial has 19 study locations across Alabama, California, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06481306's enrollment target sits among peer trials
184 50th of 283 higher than 234 of 283 other Healthy Volunteers trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI